Skip to main content Accessibility help
×
Home

Infection Control Recommendations for Patients With Cystic Fibrosis: Microbiology, Important Pathogens, and Infection Control Practices to Prevent Patient-to-Patient Transmission

  • Lisa Saiman (a1), Jane Siegel (a2) and Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants

Extract

Infection Control Recommendations for Patients With Cystic Fibrosis: Microbiology, Important Pathogens, and Infection Control Practices to Prevent Patient-to-Patient Transmission updates, expands, and replaces the consensus statement, Microbiology and Infectious Disease in Cystic Fibrosis published in 1994. This consensus document presents background data and evidence-based recommendations for practices that are intended to decrease the risk of transmission of respiratory pathogens among CF patients from contaminated respiratory therapy equipment or the contaminated environment and thereby reduce the burden of respiratory illness. Included are recommendations applicable in the acute care hospital, ambulatory, home care, and selected non-healthcare settings. The target audience includes all healthcare workers who provide care to CF patients. Antimicrobial management is beyond the scope of this document.

Copyright

Corresponding author

6931 Arlington Road, Bethesda, MD 20814; telephone: (800) FIGHT-CF; website:www. info@cff.org.

References

Hide All
1.Cystic Fibrosis Consensus Conference May 17-18, 1994. Microbiology and Infectious Disease in Cystic Fibrosis. Cystic Fibrosis Foundation; Volume V, Section 1:126.
2.Garner, JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1996;17:5380.
3.Cystic Fibrosis Foundation. Patient Registry 1995. In: Annual Report. Bethesda, MD: Cystic Fibrosis Foundation; 1996.
4.Cystic Fibrosis Foundation. Patient Registry 1996. In: Annual Report. Bethesda, MD: Cystic Fibrosis Foundation; 1997.
5.Cystic Fibrosis Foundation. Patient Registry 1997. In: Annual Report. Bethesda, MD; 1998.
6.Cystic Fibrosis Foundation. Patient Registry 1998. In: Annual Report. Bethesda, MD: Cystic Fibrosis Foundation; 1999.
7.Cystic Fibrosis Foundation. Patient Registry 1999. In: Annual Report. Bethesda, MD: Cystic Fibrosis Foundation; 2000.
8.Cystic Fibrosis Foundation. Patient Registry 2000. In: Annual Report. Bethesda, MD: Cystic Fibrosis Foundation; 2001.
9.Cystic Fibrosis Foundation. Patient Registry 2001. In: Annual Report. Bethesda, MD: Cystic Fibrosis Foundation; 2002.
10.Burns, JL, Emerson, J, Stapp, JR, et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis. 1998;27:158-63.
11.McMenamin, JD, Zaccone, TM, Coenye, T, Vandamme, P, LiPuma, JJ. Misidentification of Burkholderia cepacia in US cystic fibrosis treatment centers: an analysis of 1,051 recent sputum isolates. Chest. 2000;117:1661-5.
12.Boyce, JM, Pittet, D. Hand hygiene and patient care: pursuing the Semmelweis legacy. The Lancet Infect Diseases. 2001;920.
13.Boyce, JM, Pittet, D. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep. 2002;51:145.
14.Rutala, WA, Weber, DJ. Principles of disinfecting patient-care items. In: Rutala, WA, ed. Disinfection, Sterilization and Antisepsis in Health Care. Champlain, NY: Polyscience Publications; 1998:133149.
15.Rutala, WA, Weber, DJ, HICPAC. Guideline for disinfection and sterilization in healthcare facilities. In press.
16.Frederiksen, B, Koch, C, Hoiby, N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol. 1997;23:330-5.
17.Nixon, GM, Armstrong, DS, Carzino, R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr. 2001;138:699704.
18.Ratjen, F, Doring, G, Nikolaizik, WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet. 2001;358:983-4.
19.Burns, JL, Saiman, L, Whittier, S, et al. Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagn Microbiol Infect Dis. 2001;39:257–60.
20.NCCLS. Performance Standards for Antimicrobial Susceptibility Testing; 11th Informational Supplement. Vol. 21, NCCLS document M100-S11. Wayne, PA: NCCLS, 2001.
21.Saiman, L, Burns, JL, Whittier, S, Krzewinski, J, Marshall, SA, Jones, RN. Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J Clin Microbiol. 1999;37:2987-91.
22.Chen, JS, Witzmann, K, Spilker, T, Fink, R, LiPuma, JJ. Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis. J Pediatr. 2001;139:643-9.
23.IiPuma, JJ, Marks-Austin, KA, Holsclaw, DS Jr, Winnie, GB, Gilligan, PH, Stull, TL. Inapparent transmission of Pseudomonas (Burkholderia) cepacia among patients with cystic fibrosis. Pediatr Infect Dis J. 1994;13:716-9.
24.Mahenthiralingam, E, Campbell, ME, Foster, J, Lam, JS, Speert, DP. Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis1. J Clin Microbiol. 1996;34:1129-35.
25.Speert, DP, International Pseudomonas aeruginosa Typing Study Group. A multicenter comparison of methods for typing strains of Pseudomonas aeruginosa predominantly from patients with cystic fibrosis. J Infect Dis. 1994;169:134-42.
26.LiPuma, JJ. Burkholderia cepacia epidemiology and pathogenesis: implications for infection control. Curr Opin Pulm Med. 1998;4:337–41.
27.LiPuma, JJ, Spilker, T, Gill, LH, Campbell, PW III, Liu, L, Mahenthiralingam, E. Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis. Am J Respir Crit Care Med. 2001;164:926.
28.Bernhardt, S, Spilker, T, LiPuma, JJ. Strain variation during chronic Burkholderia species infection in cystic fibrosis. Submitted.
29.Massion, PP, Hebert, CA, Leong, S, et al. Staphylococcus aureus stimulates neutrophil recruitment by stimulating interleukin-8 production in dog trachea. Am J Physiol. 1995;268:L85–94.
30.Mahenthiralingam, E, Vandamme, P, Campbell, ME, et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis. 2001;33:1469-75.
31.Cheng, K, Smyth, RL, Govan, JR, et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet. 1996;348:639-42.
32.Farrell, PM, Shen, G, Splaingard, M, et al.. Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis. Pediatrics. 1997;100:E2.
33.Hunfeld, KP, Schmidt, C, Krackhardt, B, et al. Risk of Pseudomonas aeruginosa cross-colonization in patients with cystic fibrosis within a holiday camp—a molecular-epidemiological study. Wien Klin Wochenschr. 2000;112:329-33.
34.Jones, AM, Govan, JR, Doherty, CJ, et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet. 2001;358:557-8.
35.McCallum, SJ, Corkill, J, Gallagher, M, Ledson, MJ, Hart, CA, Walshaw, MJ. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P. aeruginosa. Lancet. 2001;358:558-60.
36.Ojeniyi, B, Frederiksen, B, Hoiby, N. Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp. Pediatr Pulmonol. 2000;29:177-81.
37.Pedersen, SS, Koch, C, Hoiby, N, Rosendal, K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother. 1986;17:505-16.
38.Krzewinksi, JW, Nguyen, CD, Foster, JM, Burns, JL. Use of random amplified polymorphic DNA polymerase chain reaction to determine the epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis. J Clin Microbiol. 2001;39:3597-602.
39.Moissenet, D, Baculard, A, Valdn, M, et al. Colonization by Alcaligenes xylosoxidans in children with cystic fibrosis: a retrospective clinical study conducted by means of molecular epidemiological investigation. Clin Infect Dis. 1997;24:274-5.
40.Valdezate, S, Vindel, A, Maiz, L, Baquero, F, Escobar, H, Canton, R. Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid, 1991-1998. Emerg Infect Dis. 2001;7:113-21.
41.Gaynes, RP. Surveillance of nosocomial infections. In: Bennett, JV, Brachman, PS, eds. Hospital Infections. Philadelphia, PA: Lippincott-Raven; 1998:6584.
42.Perl, TM. Surveillance, reporting, and use of computers in prevention and control of noscomial infections. In: Wenzel, RP, ed. Prevention and Control of Nosocomial Infections. 4th ed. Baltimore, MD: Williams and Wilkins; 1997:127-61.
43.Pottinger, JM, Herwaldt, LA, Perl, TM. Basics of surveillance—an overview. Infect Control Hosp Epidemiol. 1997;18:513-27.
44. Guidelines for Environmental Infection Control in Healthcare Facilities, 2001. Hospital Infection Control Practices Advisory Committee (HICPAC). In press.
45.Guidelines for prevention of nosocomial pneumonia. Resp Care. 1994;39:11911236.
46.Bolyard, EA, Tablan, OC, Williams, WW, Pearson, ML, Shapiro, CN, Deitchmann, SD. Guideline for infection control in healthcare personnel, 1998. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1998;19:407-63.
47.McNeil, SA, Foster, CL, Hedderwick, SA, Kauffman, CA. Effect of hand cleansing with antimicrobial soap or alcohol-based gel on microbial colonization of artificial fingernails worn by health care workers. Clin Infect Dis. 2001;32:367-72.
48.Passaro, DJ, Waring, L, Armstrong, R, et al. Postoperative Serratia marcescens wound infections traced to an out-of- hospital source. J Infect Dis. 1997;175:992-5.
49.Parry, MF, Grant, B, Yukna, M, et al. Candida osteomyelitis and diskitis after spinal surgery: an outbreak that implicates artificial nail use. Clin Infect Dis. 2001;32:352-7.
50.Moolenaar, RL, Crutcher, JM, San Joaquin, VH, et al. A prolonged outbreak of Pseudomonas aeruginosa in a neonatal intensive care unit: did staff fingernails play a role in disease transmission? Infect Control Hosp Epidemiol. 2000;21:80-5.
51.Foca, M, Jakob, K, Whittier, S, et al. Endemic Pseudomonas aeruginosa infection in a neonatal intensive care unit. N Engl J Med. 2000;343:695700.
52.Walsh, NM, Casano, AA, Manangan, LP, Sinkowitz-Cochran, RL, Jarvis, WR. Risk factors for Burkholderia cepacia complex colonization and infection among patients with cystic fibrosis. J Pediatr. 2002;141:512-7.
53.Hamill, RJ, Houston, ED, Georghiou, PR, et al. An outbreak of Burkholderia (formerly Pseudomonas) cepacia respiratory tract colonization and infection associated with nebulized albuterol therapy. Ann Intern Med. 1995;122:762-66.
54.Crespo, A, Axelrod, P, St. John, K, et al. An epidemic of Burkholderia cepacia pneumonia linked to specific practices in the handling of albuterol for nebulizers. Presented at the 12th annual meeting of the Society for Healthcare Epidemiology of America (SHEA); April 8, 2001; Salt Lake City, Utah.
55.Mertz, JJ, Scharer, L, McClement, JH. A hospital outbreak of Klebsiella pneumonia from inhalation therapy with contaminated aerosol solutions. Am Rev Respir Dis. 1967;95:454-60.
56.Ramsey, AH, Skonieczny, P, Coolidge, DT, Kurzynski, TA, Proctor, ME, Davis, JP. Burkholderia cepacia lower respiratory tract infection associated with exposure to a respiratory therapist. Infect Control Hosp Epidemiol. 2001;22:423-6.
57.Sanders, CV Jr, Luby, JP, Johanson, WG Jr, Barnett, JA, Sanford, JP. Serratia marcescens infections from inhalation therapy medications: nosocomial outbreak. Ann Intern Med. 1970;73:1521.
58.Hoffmann, KK, Weber, DJ, Rutala, WA. Pseudo epidemic of Rhodotorula rubra in patients undergoing fiberoptic bronchoscopy. Infect Control Hosp Epidemiol. 1989;10:511-4.
59.Favero, MS, Carson, LA, Bond, WW, Petersen, NJ. Pseudomonas aeruginosa: growth in distilled water from hospitals. Science. 1971;173:836-8.
60.Carson, LA, Favero, MS, Bond, WW, Petersen, NJ. Morphological, biochemical, and growth characteristics of pseudomonas cepacia from distilled water. Appl Microbiol. 1973 ;25:476-83.
61.Hutchinson, GR, Parker, S, Pryor, JA, et al. Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis. J Clin Microbiol. 1996;34:584-7.
62.Pitchford, KC, Corey, M, Highsmith, AK, et al. Pseudomonas species contamination of cystic fibrosis patients' home inhalation equipment. J Pediatr. 1987;111:212-6.
63.Rosenfeld, M, Joy, P, Nguyen, CD, Krzewinkski, JW, Burns, JL. Cleaning home nebulizers used by patients with cystic fibrosis: is rinsing with tap water enough? J Hosp Infect. 2001;49:229-30.
64.Jakobsson, BM, Onnered, AB, Hjelte, L, Nystrom, B. Low bacterial contamination of nebulizers in home treatment of cystic fibrosis patients. J Hosp Infect. 1997;36:201-7.
65.Merritt, K, Hitchins, VM, Brown, SA. Safety and cleaning of medical materials and devices. J Biomed Mater Res. 2000;53:131-6.
66.Best, M, Sattar, SA, Springthorpe, VS, Kennedy, ME. Comparative mycobactericidal efficacy of chemical disinfectants in suspension and carrier tests. Appl Environ Microbiol. 1988;54:2856-8.
67.Luebbert, P. Home care. In: Ja, P, ed. Association for Professionals in Infection Control (APIC) Text of Infection Control and Epidemiology. Washington, DC: Association for Professionals in Infection Control and Epidemiology Inc; 2000:47.
68.Karapinar, M, Gonul, SA. Effects of sodium bicarbonate, vinegar, acetic and citric acids on growth and survival of Yersinia enterocolitica. Int J Food Microbiol. 1992;16:343-7.
69.Rutala, WA, Barbee, SL, Aguiar, NC, Sobsey, MD, Weber, DJ. Antimicrobial activity of home disinfectants and natural products against potential human pathogens. Infect Control Hosp Epidemiol. 2000;21:33-8.
70.Mangram, A, Jarvis, WR. Nosocomial Burkholderia cepacia outbreaks and pseudo-outbreaks. Infect Control Hosp Epidemiol. 1996;17:718-20.
71.Cefai, C, Richards, J, Gould, FK, McPeake, P. An outbreak of Acinetobacter respiratory tract infection resulting from incomplete disinfection of ventilatory equipment. J Hosp Infect. 1990;15:177-82.
72.Gurevich, I, Tafuro, P, Ristuccia, P, Herrmann, J, Young, AR, Cunha, BA. Disinfection of respirator tubing: a comparison of chemical versus hot water machine-assisted processing. J Hosp Infect. 1983;4:199208.
73.Rosaspina, S, Salvatorelli, G, Anzanel, D. The bactericidal effect of microwaves on Mycobacterium bovis dried on scalpel blades. J Hosp Infect. 1994;26:4550.
74.Rosaspina, S, Salvatorelli, G, Anzanel, D, Bovolenta, R. Effect of microwave radiation on Candida albicans. Microbios. 1994;78:55-9.
75.Sanborn, MR, Wan, SK, Bulard, R. Microwave sterilization of plastic tissue culture vessels for reuse. Appl Environ Microbiol. 1982;44:960-4.
76.Tablan, OC, Chorba, TL, Schidlow, DV, et al. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr. 1985;107:382-7.
77.Recommendations of the Clinical Subcommittee of the Medical/Scientific Advisory Committee of the Canadian CF Foundation. Microbiological processing of respiratory specimens from patients with cystic fibrosis. Can J Infect Dis. 1993;4:166169.
78.Medical/Scientific Advisory Committee of the Canadian CF Foundation. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis. Can J Infect Dis. 1993;4:163-65.
79. Cystic Fibrosis Trust Infection Control Group: a statement on Burkholderia cepacia. UK Cystic Fibrosis Trust. 1999.
80.Doring, G, Schaffar, L eds. Epidemiology of Pulmonary Infections by Pseudomonas in Patients With Cystic Fibrosis: A Consensus Report. Paris, France: AFLM; 1993.
81.Valerius, NH, Koch, C, Hoiby, N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 1991;338:725-6.
82.Hoiby, N, Pedersen, SS. Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients. Acta Paediatr Scand. 1989;78:395404.
83.Frederiksen, B, Koch, C, Hoiby, N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol. 1999;28:159-66.
84.Pedersen, SS, Jensen, T, Hoiby, N, Koch, C, Flensborg, EW. Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients. Acta Paediatr Scand. 1987;76:955-61.
85.Jernigan, JA, Clemence, MA, Stott, GA, et al. Control of methicillin-resistant Staphylococcus aureus at a university hospital: one decade later. Infect Control Hosp Epidemiol. 1995;16:686-96.
86.Jernigan, JA, Titus, MG, Groschel, DH, Getchell-White, S, Farr, BM. Effectiveness of contact isolation during a hospital outbreak of methicillin-resistant Staphylococcus aureus. Am J Epidemiol. 1996;143:496504.
87.Chaix, C, Durand-Zaleski, I, Alberti, C, Brun-Buisson, C. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA. 1999;282:1745-51.
88.Puzniak, LA, Leet, T, Mayfield, J, Kollef, M, Mundy, LM. To gown or not to gown: the effect on acquisition of vancomycin- resistant enterococci. Clin Infect Dis. 2002;35:1825.
89.Shay, DK, Maloney, SA, Montecalvo, M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis. 1995;172:9931000.
90.Montecalvo, MA, Jarvis, WR, Uman, J, et al. Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting. Ann Intern Med. 1999;131:269-72.
91.Boyce, JM, Opal, SM, Chow, JW, et al. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol. 1994;32:1148-53.
92.Jochimsen, EM, Fish, L, Manning, K, et al. Control of vancomycin-resistant enterococci at a community hospital: efficacy of patient and staff cohorting. Infect Control Hosp Epidemiol. 1999;20:106-9.
93.Macartney, KK, Gorelick, MH, Manning, ML, Hodinka, RL, Bell, LM. Nosocomial respiratory syncytial virus infections: the cost-effectiveness and cost-benefit of infection control. Pediatrics. 2000;106:520-6.
94.Leclair, JM, Freeman, J, Sullivan, BF, Crowley, CM, Goldmann, DA. Prevention of nosocomial respiratory syncytial virus infections through compliance with glove and gown isolation precautions. N Engl J Med. 1987;317:329-34.
95.Ostrowsky, BE, Trick, WE, Sohn, AH, et al. Control of vancomycin-resistant enterococcus in health care facilities in a region. N Engl J Med. 2001;344:1427-33.
96.Pittet, D, Hugonnet, S, Harbarth, S, et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet. 2000;356:1307-12.
97.Kretzer, EK, Larson, EL. Behavioral interventions to improve infection control practices. Am J Infect Control. 1998;26:245-53.
98.Larson, EL, Early, E, Cloonan, P, Sugrue, S, Parides, M. An organizational climate intervention associated with increased hand washing and decreased nosocomial infections. Behav Med. 2000;26:14-22.
99.Pettinger, A, Nettleman, MD. Epidemiology of isolation precautions. Infect Control Hosp Epidemiol. 1991;12:303-7.
100.Fitz-Simmons, SC. The changing epidemiology of cystic fibrosis. J Pediatr. 1993;122:19.
101.Gilligan, PH. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev. 1991;4:3551.
102.Govan, JR, Brown, PH, Maddison, J, et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet. 1993;342:15-9.
103.Rosenfeld, M, Gibson, RL, McNamara, S, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol. 2001;32:356-66.
104.Wong, K, Roberts, MC, Owens, L, Fife, M, Smith, AL. Selective media for the quantitation of bacteria in cystic fibrosis sputum. J Med Microbiol. 1984;17:113-9.
105.Chapin, KC, Murray, PR. Media. In: Murray, PR, Baron, EJ, Pfaller, MA, Tenover, FC, Yolken, RH, eds. Manual of Clinical Microbiology. 7th ed. Washington DC: ASM Press; 1999:16871707.
106.Kilbourn, JP, Campbell, RA, Grach, JL, Willis, MD. Quantitative bacteriology of sputum. Am Rev Resp Dis. 1968;98:810-8.
107.Gilligan, PH, Gage, PA, Bradshaw, LM, Schidlow, DV, DeCicco, BT. Isolation medium for the recovery of Pseudomonas cepacia from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol. 1985;22:58.
108.Welch, DF, Muszynski, MJ, Pai, CH, et al. Selective and differential medium for recovery of Pseudomonas cepacia from the respiratory tracts of patients with cystic fibrosis. J Clin Microbiol. 1987;25:1730-4.
109.Tablan, OC, Carson, LA, Cusick, LB, Bland, LA, Martone, WJ, Jarvis, WR. Laboratory proficiency test results on use of selective media for isolating Pseudomonas cepacia from simulated sputum specimens of patients with cystic fibrosis. J Clin Microbiol. 1987;25:485-7.
110.Henry, DA, Campbell, ME, LiPuma, JJ, Speert, DP. Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium. J Clin Microbiol. 1997;35:614-9.
111.Henry, D, Campbell, M, McGimpsey, C, et al. Comparison of isolation media for recovery of Burkholderia cepacia complex from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol. 1999;37:1004-7.
112.Kloos, WE, Bannerman, TL. Staphylococcus and micrococcus. In: Murray, PR, Baron, EJ, Pfaller, MA, Tenover, FC, Yolken, RH, eds. Manual of Clinical Microbiology. 7 ed. Washington, DC: ASM Press; 1999:264287.
113.Swenson, JM, Hindler, JA, Peterson, LR. Special phenotypic methods for detecting antibacterial resistance. In: Murray, PR, Baron, EJ, Pfaller, MA, Tenover, FC, Yolken, RH, eds. Manual of Clinical Microbiology. 7th ed. Washington, DC: ASM Press; 1999:1563-77.
114.Gilligan, PH, Whittier, S. Burkholderia, Stenotrophomonas, Raltonia, Brevundimonas, Comamonas and Acidovorax. In: Murray, PR, Baron, EJ, Pfaller, MA, Tenover, FC, Yolken, RH, eds. Manual of Clinical Microbiology. 7 ed. Washington, DC: ASM Press; 1999:526-38.
115.Denton, M, Hall, MJ, Todd, NJ, Kerr, KG, Littlewood, JM. Improved isolation of Stenotrophomonas maltophilia from the sputa of patients with cystic fibrosis using a selective medium. Clin Microbiol Infect. 2000;6:397-8.
116.Whittier, S, Hopfer, RL, Knowles, MR, Gilligan, PH. Improved recovery of mycobacteria from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol. 1993;31:861-4.
117.Whittier, S, Olivier, K, Gilligan, P, Knowles, M, Della-Latta, P. Proficiency testing of clinical microbiology laboratories using modified decontamination procedures for detection of nontuberculous mycobacteria in sputum samples from cystic fibrosis patients. The Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. J Clin Microbiol. 1997;35:2706-8.
118.Bange, FC, Kirschner, P, Bottger, EC. Recovery of mycobacteria from patients with cystic fibrosis. J Clin Microbiol. 1999;37:3761-3.
119.Burns, JL, Saiman, L, Whittier, S, et al. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol. 2000;38:1818-22.
120.Tenover, FC, Arbeit, RD, Goering, RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33:2233-9.
121.Morel, AS, Saiman, L. The role of molecular epidemiologic typing in pediatric infection control. Semin Pediatr Infect Dis. 2001;12:100-6.
122.Ogle, JW, Janda, JM, Woods, DE, Vasil, ML. Characterization and use of a DNA probe as an epidemiological marker for Pseudomonas aeruginosa. J Infect Dis. 1987;155:119-26.
123.Mahenthiralingam, E, Campbell, ME, Speert, DP. Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis. Infect Immun. 1994;62:596605.
124.Hancock, RE, Mutharia, LM, Chan, L, Darveau, RP, Speert, DP, Pier, GB. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypeable strains deficient in lipopolysac-charide O side chains. Infect Immun. 1983;42:170-7.
125.Thomassen, MJ, Demko, CA, Boxerbaum, B, Stern, RC, Kuchenbrod, PJ. Multiple isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J Infect Dis. 1979;140:873-80.
126.Burns, JL, Gibson, RL, McNamara, S, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis. 2001;183:444-52.
127.Ojeniyi, B, Lam, JS, Hoiby, N, Rosdahl, VT. A comparison of the efficiency in serotyping of Pseudomonas aeruginosa from cystic fibrosis patients using monoclonal and polyclonal antibodies. APMIS. 1989;97:631-6.
128.Schlichting, C, Branger, C, Fournier, JM, et al. Typing of Staphylococcus aureus by pulsed-field gel electrophoresis, zymotyping, capsular typing, and phage typing: resolution of clonal relationships. J Clin Microbiol. 1993;31:227-32.
129.Goerke, C, Kraning, K, Stern, M, Doring, G, Botzenhart, K, Wolz, C. Molecular epidemiology of community-acquired Staphylococcus aureus in families with and without cystic fibrosis patients. J Infect Dis. 2000;181:984-9.
130.LiPuma, JJ, Mortensen, JE, Dasen, SE, et al. Ribotype analysis of Pseudomonas cepacia from cystic fibrosis treatment centers. J Pediatr. 1988;113:859-62.
131.Mahenthiralingam, E, Simpson, DA, Speert, DP. Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis. J Clin Microbiol. 1997;35:808-16.
132.Mahenthiralingam, E, Bischof, J, Byrne, SK, et al. DNA-Based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia sta-bilis, and Burkholderia cepacia genomovars I and III. J Clin Microbiol. 2000;38:3165-73.
133.Gaynes, RP, Emori, TG. Surveillance for nosocomial infections. In: Abrutyn, E, Goldmann, DA, Scheckler, WE, eds. Saunders Infection Control Reference Service. Philadelphia, PA: WB Saunders Co; 2001:40-4.
134.Wenzel, RP, Nettleman, MD. Principles of hospital epidemiology. In: Mayhall, CG, ed. Hospital Epidemiology and Infection Control. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:81-8.
135.Doring, G, Conway, SP, Heijerman, HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000;16:749-67.
136.Shreve, MR, Butler, S, Kaplowitz, HJ, et al. Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis. J Clin Microbiol. 1999;37:753-7.
137.Johnson, C, Butler, S, Konstan, M, Morgan, W, Wohl, ME. Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest. 2003;123:20-7.
138.LiPuma, JJ. Burkholderia cepacia. Management issues and new insights. Clin Chest Med. 1998, ;19:473-86, vi.
139.Miall, LS, McGinley, NT, Brownlee, KG, Conway, SP. Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis. Arch Dis Child. 2001;84:160-2.
140.Givney, R, Vickery, A, Holliday, A, Pegler, M, Benn, R. Methicillin-resistant Staphylococcus aureus in a cystic fibrosis unit. J Hosp Infect. 1997;35:2736.
141.Saiman, L, Hiatt, P. Cystic fibrosis. In: Feigin, RD, Cherry, JD, eds. Textbook of Pediatric Infectious Diseases. In press.
142.Ramsey, BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med. 1996;335:179-88.
143.Ramsey, BW, Pepe, MS, Quan, JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999;340:2330.
144.Stutman, HR, Lieberman, JM, Nussbaum, E, Marks, MI. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatr. 2002;140:299305.
145.McKenney, D, Pouliot, KL, Wang, Y, et al. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science. 1999;284:1523-7.
146.Cramton, SE, Ulrich, M, Gotz, F, Doring, G. Anaerobic conditions induce expression of polysaccharide intercellular adhesin in Staphylococcus aureus and Staphylococcus epidermidis. Infect Immun. 2001;69:4079-85.
147.Kahl, B, Herrmann, M, Everding, AS, et al. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis. 1998;177:1023-9.
148.Ulrich, M, Herbert, S, Berger, J, et al. Localization of Staphylococcus aureus in infected airways of patients with cystic fibrosis and in a cell culture model of S. aureus adherence. Am J Respir Cell Mol Biol. 1998;19:8391.
149.Imundo, L, Barasch, J, Prince, A, Al-Awqati, Q. Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci USA. 1995;92:3019-23.
150.Ben-Ari, J, Gozal, D, Dorio, RJ, Bowman, CM, Reiff, A, Walker, SM. Superantigens and cystic fibrosis: resistance of presenting cells to dexamethasone. Clin Diagn Lab Immunol. 2000;7:553-6.
151.Anderson, DH. Therapy and prognosis of fibrocystic disease of the pancreas. Pediatrics. 1949;3:406-17.
152.Shinefield, H, Black, S, Fattom, A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med. 2002;346:491-6.
153.von Eiff, C, Becker, K, Machka, K, Stammer, H, Peters, G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. 2001;344:11-6.
154.Perl, TM, Roy, MC. Postoperative wound infections: risk factors and role of Staphylococcus aureus nasal carriage. J Chemother. 1995;7(suppl 3):2935.
155.Perl, TM, Cullen, JJ, Wenzel, RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med. 2002;346:1871-7.
156.Branger, C, Gardye, C, Lambert-Zechovsky, N. Persistence of Staphylococcus aureus strains among cystic fibrosis patients over extended periods of time. J Med Microbiol. 1996;45:294301.
157.Lowy, FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520-32.
158.Sattler, CA, Mason, EJ, Kaplan, S. Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr Infect Dis J. 2002;21:910-16.
159.Hussain, FM, Boyle-Vavra, S, Bethel, CD, Daum, RS. Current trends in community-acquired methicillin-resistant Staphylococcus aureus at a tertiary care pediatric facility. Pediatr Infect Dis J. 2000;19:1163-6.
160.Herold, BC, Immergluck, LC, Maranan, MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA. 1998;279:593-8.
161.Naimi, TS, LeDell, KH, Boxrud, DJ, et al. Epidemiology and clonality of community-acquired methicillin resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis. 2001;33:990-96.
162.Baba, T, Takeuchi, F, Kuroda, M, et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet. 2002;359:1819-27.
163.Abi-Hanna, P, Frank, AL, Quinn, JP, et al. Clonal features of community-acquired methicillin-resistant Staphylococcus aureus in children. Clin Infect Dis. 2000;30:630-1.
164.Boyce, JM. Are the epidemiology and microbiology of methicillin-resistant Staphylococcus aureus changing? JAMA. 1998;279:623-4.
165.Akram, J, Glatt, AE. True community-acquired methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol. 1998;19:106-7.
166.Sumrall, B, Nolan, R. Retrospective study of community acquired (CA) methicillin-resistant Staphylococcus aureus (MRSA) occurring during an epidemic of MRSA at a Veterans Affairs hospital. Infect Control Hosp Epidemiol. 1996;15(suppl, part2):28.
167.Edmond, MB, Wenzel, RP, Pasculle, AW. Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Ann Intern Med. 1996;124:329-34.
168.Boyce, JM, Potter-Bynoe, G, Chenevert, C, King, T. Environmental contamination due to methicillin-resistant Staphylococcus aureus: possible infection control implications. Infect Control Hosp Epidemiol. 1997;18:622-7.
169.Bell, M, Seiber, K, Weatherly, M, Jarvis, W. Infection control and the cystic fibrosis population: a survey of prevailing practices. Infect Control Hosp Epidemiol. Submitted.
170.Thomas, SR, Gyi, KM, Gaya, H, Hodson, ME. Methicillin-resistant Staphylococcus aureus: impact at a national cystic fibrosis centre. J Hosp Infect. 1998;40:203-9.
171.Boxerbaum, B, Jacobs, MR, Cechner, RL. Prevalence and significance of methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis. Pediatr Pulmonol. 1988;4:159-63.
172.Abman, SH, Ogle, JW, Harbeck, RJ, Butler-Simon, N, Hammond, KB, Accurso, FJ. Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening. J Pediatr. 1991;119:211-7.
173.Hudson, VL, Wielinski, CL, Regelmann, WE. Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of 2 years. J Pediatr. 1993;122:854-60.
174.Kosorok, MR, Zeng, L, West, SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol. 2001;32:277-87.
175.Henry, RL, Mellis, CM, Petrovic, L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol. 1992;12:158-61.
176.Parad, RB, Gerard, CJ, Zurakowski, D, Nichols, DP, Pier, GB. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect Immun. 1999;67:4744-50.
177.West, SE, Zeng, L, Lee, BL, et al. Respiratory infection with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA. 2002;287:2958-67.
178.Saiman, L, Mehar, F, Niu, WW, et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis. 1996;23:532-7.
179.Ojeniyi, B, Petersen, US, Hoiby, N. Comparison of genome fingerprinting with conventional typing methods used on Pseudomonas aeruginosa isolates from cystic fibrosis patients. APMIS. 1993;101:168-75.
180.Romling, U, Fiedler, B, Bosshammer, J, et al. Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis. J Infect Dis. 1994;170:1616-21.
181.Wolz, C, Kiosz, G, Ogle, JW, et al. Pseudomonas aeruginosa cross-colonization and persistence in patients with cystic fibrosis. Use of a DNA probe. Epidemiol Infect. 1989;102:205-14.
182.Zimakoff, J, Hoiby, N, Rosendal, K, Guilbert, JP. Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic. J Hosp Infect. 1983;4:3140.
183.Botzenhart, K, Doring, G. Epidemiology and ecology of Pseudomonas aeruginosa. In: Pseudomonas aeruginosa as an Opportunistic Pathogen. New York: Plenum; 1993:118.
184.Doring, G, Jansen, S, Noll, H, et al. Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward. Pediatr Pulmonol. 1996;21:90100.
185.Romling, U, Wingender, J, Muller, H, Tummler, B. A major Pseudomonas aeruginosa clone common to patients and aquatic habitats. Appl Environ Microbiol. 1994;60:1734-8.
186.Speert, DP, Campbell, ME. Hospital epidemiology of Pseudomonas aeruginosa from patients with cystic fibrosis. J Hosp Infect. 1987;9:1121.
187.Bosshammer, J, Fiedler, B, Gudowius, P, von der Hardt, H, Romling, U, Tummler, B. Comparative hygienic surveillance of contamination with pseudomonads in a cystic fibrosis ward over a 4-year period. J Hosp Infect. 1995;31:261-74.
188.Doring, G, Ulrich, M, Muller, W, et al. Generation of Pseudomonas aeruginosa aerosols during hand washing from contaminated sink drains, transmission to hands of hospital personnel, and its prevention by use of a new heating device. Zentralbl Hyg Umweltmed. 1991;191:494505.
189.Govan, JR, Nelson, JW. Microbiology of lung infection in cystic fibrosis. Br Med Bull. 1992;48:912-30.
190.Berrouane, YF, McNutt, LA, Buschelman, BJ, et al. Outbreak of severe Pseudomonas aeruginosa infections caused by a contaminated drain in a whirlpool bathtub. Clin Infect Dis. 2000;31:1331-7.
191.Fiorillo, L, Zucker, M, Sawyer, D, Lin, AN. The Pseudomonas hot-foot syndrome. N Engl J Med. 2001;345:335-8.
192.Jensen, ET, Giwercman, B, Ojeniyi, B, et al. Epidemiology otPseudomonas aeruginosa in cystic fibrosis and the possible role of contamination by dental equipment. J Hosp Infect. 1997;36:117-22.
193.Thomassen, MJ, Demko, CA, Doershuk, CF, Stern, RC, Klinger, JD. Pseudomonas cepacia: decrease in colonization in patients with cystic fibrosis. Am Rev Resp Dis. 1986;134:669-71.
194.Grothues, D, Koopmann, U, von der Hardt, H, Tummler, B. Genome fingerprinting of Pseudomonas aeruginosa indicates colonization of cystic fibrosis siblings with closely related strains. J Clin Microbiol. 1988;26:1973-7.
195.Fluge, O, Ojeniyi, B, Hoiby, N, et al. Typing of Pseudomonas aeruginosa strains in Norwegian cystic fibrosis patients. Clin Microbiol Infect. 2001;7:238-43.
196.Farrell, PM, Kosorok, MR, Laxova, A, et al. Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. NEngl J Med. 1997;337:963-9.
197.Kosorok, MR, Jalaluddin, M, Farrell, PM, et al. Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis. Pediatr Pulmonol. 1998;26:81-8.
198.Speert, DP, Lawton, D, Damm, S. Communicability of Pseudomonas aeruginosa in a cystic fibrosis summer camp. J Pediatr. 1982;101:227-8.
199.Williams, T. Evaluation of antimicrobial sensitivity patterns as markers of Pseudomonas aeruginosa cross-infection at a cystic fibrosis clinic. Br J Biomed Sci. 1997;54:181-5.
200.Speert, DP, Campbell, ME, Henry, DA, et al. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada. Am J Respir Crit Care Med. 2002;166:988-93.
201.McCallum, SJ, Gallagher, MJ, Corkill, JE, Hart, CA, Ledson, MJ, Walshaw, MJ. Spread of an epidemic Pseudomonas aeruginosa strain from a patient with cystic fibrosis (CF) to non-CF relatives. Thorax. 2002;57:559-60.
202.Coenye, T, Vandamme, P, Govan, JRW, LiPuma, JJ. Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol. 2001:34273436.
203.Speert, DP, Henry, D, Vandamme, P, Corey, M, Mahenthiralingam, E. Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis in Canada: geographical distribution and clustering of strains. Emerg Infect Dis. 2002;8:181-7.
204.Isles, A, Maclusky, I, Corey, M, et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr. 1984;104:206-10.
205.Tablan, OC, Martone, WJ, Doershuk, CF, et al. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes. Chest. 1987;91:527-32.
206.Kazachkov, M, Lager, J, LiPuma, J, Barker, PM. Survival following Burkholderia cepacia sepsis in a patient with cystic fibrosis treated with corticosteroids. Pediatr Pulmonol. 2001;32:338-40.
207.Drabick, JA, Gracely, EJ, Heidecker, GJ, LiPuma, JJ. Survival of Burkholderia cepacia on environmental surfaces. J Hosp Infect. 1996;32:267-76.
208.Corey, M, Farewell, V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol. 1996;143:1007-17.
209.Liou, TG, Adler, FR, Fitz-Simmons, SC, Cahill, BC, Hibbs, JR, Marshall, BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001;153:345-52.
210.Navarro, J, Rainisio, M, Harms, HK, et al. Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European Epidemiologic Registry of Cystic Fibrosis. Eur Respir J. 2001;18:298305.
211.Rosenfeld, M, Davis, R, Fitz-Simmons, S, Pepe, M, Ramsey, B. Gender gap in cystic fibrosis mortality. Am J Epidemiol. 1997;145:794803.
212.Whiteford, ML, Wilkinson, JD, McColl, JH, et al. Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis followinga hospital outbreak. Thorax. 1995;50:1194-8.
213.Aris, RM, Routh, J, LiPuma, JJ, Heath, D, Gilligan, PH. Burkholderia cepacia complex in cystic fibrosis patients after lung transplantation: survival linked to genomovar type. Am J Resp Crit Care Med. 2001;164:21022106.
214.De Soyza, A, McDowell, A, Archer, L, et al. Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. Lancet. 2001;358:1780-1.
215.Ledson, MJ, Gallagher, MJ, Corkill, JE, Hart, CA, Walshaw, MJ. Cross infection between cystic fibrosis patients colonised with Burkholderia cepacia. Thorax. 1998;53:432-6.
216.Pegues, DA, Carson, LA, Tablan, OC, et al. Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. Summer Camp Study Group. J Pediatr. 1994;124:694702.
217.Pegues, DA, Schidlow, DV, Tablan, OC, Carson, LA, Clark, NC, Jarvis, WR. Possible nosocomial transmission of Pseudomonas cepacia in patients with cystic fibrosis. Arch Pediatr Adolesc Med. 1994;148:805-12.
218.LiPuma, JJ, Dasen, SE, Nielson, DW, Stern, RC, Stull, TL. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet. 1990;336:1094-6.
219.Centers for Disease Control. Pseudomonas cepacia at summer camps for persons with cystic fibrosis. MMWR Morb Mortal Wkly Rep. 1993;42:456-9.
220.Holmes, A, Nolan, R, Taylor, R, et al. An epidemic of Burkholderia cepacia transmitted between patients with and without cystic fibrosis. J Infect Dis. 1999;179:1197-205.
221.Reboli, AC, Koshinski, R, Arias, K, Marks-Austin, K, Stieritz, D, Stull, TL. An outbreak of Burkholderia cepacia lower respiratory tract infection associated with contaminated albuterol nebulization solution. Infect Control Hosp Epidemiol. 1996;17:741-3.
222.Nelson, JW, Doherty, CJ, Brown, PH, Greening, AP, Kaufmann, ME, Govan, JR. Pseudomonas cepacia in inpatients with cystic fibrosis. Lancet. 1991;338:1525.
223.Pankhurst, CL, Harrison, VE, Philpott-Howard, J. Evaluation of contamination of the dentist and dental surgery environment with Burkholderia (Pseudomonas) cepacia during treatment of children with cystic fibrosis. Int J Paediatr Dent. 1995;5:243-7.
224.Ensor, E, Humphreys, H, Peckham, D, Webster, C, Knox, AJ. Is Burkholderia (Pseudomonas) cepacia disseminated from cystic fibrosis patients during physiotherapy? J Hosp Infect. 1996;32:915.
225.Humphreys, H, Peckham, D, Patel, P, Knox, A. Airborne dissemination of Burkholderia (Pseudomonas) cepacia from adult patients with cystic fibrosis. Thorax. 1994;49:1157-9.
226.Humphreys, H, Peckhman, D. Environmental sampling to detect Burkholderia cepacia in a cystic fibrosis outpatient clinic. Eur J Clin Microbiol Infect Dis. 1996;15:523-5.
227.Burdge, DR, Nakielna, EM, Noble, MA. Case-control and vector studies of nosocomial acquisition of Pseudomonas cepacia in adult patients with cystic fibrosis. Infect Control Hosp Epidemiol. 1993;14:127-30.
228.Sun, L, Jiang, RZ, Steinbach, S, et al. The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nat Med. 1995;1:661-6.
229.Siddiqui, AH, Mulligan, ME, Mahenthiralingam, E, et al. An episodic outbreak of genetically related Burkholderia cepacia among non-cystic fibrosis patients at a university hospital. Infect Control Hosp Epidemiol. 2001;22:419-22.
230.Dy, ME, Nord, JA, LaBombardi, VJ, Germana, J, Walker, P. Lack of throat colonization with Burkholderia cepacia among cystic fibrosis healthcare workers. Infect Control Hosp Epidemiol. 1999;20:90.
231.Mortensen, JE, Fisher, MC, LiPuma, JJ. Recovery of Pseudomonas cepacia and other Pseudomonas species from the environment. Infect Control Hosp Epidemiol. 1995;16:30-2.
232.Butler, SL, Doherty, CJ, Hughes, JE, Nelson, JW, Govan, JR. Burkholderia cepacia and cystic fibrosis: do natural environments present a potential hazard? J Clin Microbiol. 1995;33:1001-4.
233.Balandreau, J, Viallard, V, Cournoyer, B, et al. Burkholderia cepacia genomovar III is a common plant-associated bacterium. Appl Environ Microbiol. 2001;67:982-85.
234.Gonzalez, CF, Mark, GL, Mahenthiralingam, E, LiPuma, JJ. Isolation of soilborne genomovar III Burkholderia cepacia and lytic phages with inter-genomovar host range. Pediatr Pulmonol. 2000;S20:288-9.
235.Bevivino, A, Dalmastri, C, Tabacchioni, S, et al. Burkholderia cepacia complex bacteria from clinical and environmental sources in Italy: genomovar status and distribution of traits related to virulence and transmissibility. J Clin Microbiol. 2002;40:846-51.
236.LiPuma, JJ, Spilker, T, Coenye, T, Gonzalez, CF. An epidemic Burkholderia cepacia complex strain identified in soil. Lancet. 2002;359:2002-3.
237.Miller, SM, Parke, JL, Bies, S, LiPuma, JJ. Detection, recovery and identification of Burkholderia cepacia from the natural environment. Pediatr Pulmonol. 2000;S20:288.
238.Fung, SK, Dick, H, Devlin, H, Tullis, E. Transmissibility and infection control implications of Burkholderia cepacia in cystic fibrosis. Can Infect Dis J. 1998;9:177-82.
239.Paul, ML, Pegler, MA, Benn, RA. Molecular epidemiology of Burkholderia cepacia in two Australian cystic fibrosis centres. J Hosp Infect. 1998;38:1926.
240.Denton, M, Kerr, KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 1998;11:5780.
241.Sattler, C, Mason, EJ, Kaplan, S. Nonrespiratory Stenotrophomonas maltophilia infection at a children's hospital. Clin Infect Dis. 2000;31:1321-30.
242.Sattler, CA. Stenotrophomonas maltophilia infection in children. Pediatr Infect Dis J. 2000;19:877-8.
243.Elting, LS, Khardori, N, Bodey, GP, Fainstein, V. Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol. 1990;11:134-8.
244.Demko, CA, Stern, RC, Doershuk, CF. Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence. Pediatr Pulmonol. 1998;25:304-8.
245.Denton, M, Todd, NJ, Kerr, KG, Hawkey, PM, Littlewood, JM. Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples. J Clin Microbiol. 1998;36:1953-8.
246.Talmaciu, I, Varlotta, L, Mortensen, J, Schidlow, DV. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr Pulmonol. 2000;30:10-5.
247.Burdge, DR, Noble, MA, Campbell, ME, Krell, VL, Speert, DP. Xanthomonas maltophilia misidentified as Pseudomonas cepacia in cultures of sputum from patients with cystic fibrosis: a diagnostic pitfall with major clinical implications. Clin Infect Dis. 1995;20:445-8.
248.Whitby, PW, Carter, KB, Burns, JL, Royall, JA, LiPuma, JJ, Stull, TL. Identification and detection of Stenotrophomonas maltophilia by rRNA-directed PCR. J Clin Microbiol. 2000;38:4305-9.
249.Saiman, L, Edwards, L. What is the association between CF pathogens and morbidity and mortality? Pediatr Pulmonol. 2000;S20:147-8.
250.Gladman, G, Connor, PJ, Williams, RF, David, TJ. Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis. Arch Dis Child. 1992;67:192-5.
251.Karpati, F, Malmborg, AS, Alfredsson, H, Hjelte, L, Strandvik, B. Bacterial colonization with Xanthomonas maltophilia—a retrospective study in a cystic fibrosis patient population. Infection. 1994;22:258-63.
252.Goss, CH, Aitken, ML, Otto, K, Rubenfeld, GD. Acquiring Stenotrophomonas maltophilia does not reduce survival in patients with cystic fibrosis. Pediatr Pulmonol. 2000;S20:101-2.
253.Saiman, L, Chen, Y, Tabibi, S, et al. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J Clin Microbiol. 2001;39:3942-5.
254.Liu, L, Coenye, T, Burns, JL, Whitby, PW, Stull, TL, LiPuma, JJ. Ribosomal DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients. J din Microbiol. 2002;40:1210-3.
255.Fabbri, A, Tacchella, A, Manno, G, Viscoli, C, Palmero, C, Gargani, GF. Emerging microorganisms in cystic fibrosis. Chemioterapia. 1987;6:32-7.
256.Dunne, WM Jr, Maisch, S. Epidemiological investigation of infections due to Alcaligenes species in children and patients with cystic fibrosis: use of repetitive-element-sequence polymerase chain reaction. Clin Infect Dis. 1995;20:836-41.
257.Vu-Thien, H, Moissenet, D, Valcin, M, Dulot, C, Tournier, G, Garbarg-Chenon, A. Molecular epidemiology of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in a cystic fibrosis center. Eur J Clin Microbiol Infect Dis. 1996;15:876-9.
258.Horsburgh, CR Jr. Epidemiology of disease caused by nontuberculous mycobacteria. Semin Respir Infect. 1996;11:244-51.
259.Falkinham, JO III. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev. 1996;9:177215.
260.Benator, DA, Gordin, FM. Nontuberculous mycobacteria in patients with human immunodeficiency virus infection. Semin Respir Infect. 1996;11:285300.
261.Newport, MJ, Huxley, CM, Huston, S, et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med. 1996;335:1941-9.
262.American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med. 1997;156:S1-25.
263.Wallace, RJ Jr, Brown, BA, Griffith, DE. Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria. Annu Rev Microbiol. 1998;52:453-90.
264.Winthrop, KL, Abrams, M, Yakrus, M, et al. An outbreak of mycobacterial furunculosis associated with footbaths at a nail salon. N Engl J Med. 2002;346:1366-71.
265.Smith, MJ, Efthimiou, J, Hodson, ME, Batten, JC. Mycobacterial isolations in young adults with cystic fibrosis. Thorax. 1984;39:369-75.
266.Kilby, JM, Gilligan, PH, Yankaskas, JR, Highsmith, WE Jr, Edwards, LJ, Knowles, MR. Nontuberculous mycobacteria in adult patients with cystic fibrosis. Chest. 1992;102:70-5.
267.Aitken, ML, Burke, W, McDonald, G, Wallis, C, Ramsey, B, Nolan, C. Nontuberculous mycobacterial disease in adult cystic fibrosis patients. Chest. 1993;103:1096-9.
268.Hjelt, K, Hojlyng, N, Howitz, P, et al. The role of mycobacteria other than tuberculosis (MOTT) in patients with cystic fibrosis. Scand Infect Dis. 1994;26:569-76.
269.Olivier, KN, Yankaskas, JR, Knowles, MR. Nontuberculous mycobacterial pulmonary disease in cystic fibrosis. Semin Respir Infect. 1996;11:272-84.
270.Olivier, K, Handler, A, Less, JH, Tudor, G, Knowles, MR. Clinical impact of nontuberculous mycobacteria on the course of cystic fibrosis lung disease: results of a multicenter nested cohort study. Pediatr Pulmonol. 2000:102-3.
271.Torrens, JK, Dawkins, P, Conway, SP, Moya, E. Non-tuberculous mycobacteria in cystic fibrosis. Thorax. 1998;53:182-5.
272.Fauroux, B, Delaisi, B, Clement, A, et al. Mycobacterial lung disease in cystic fibrosis: a prospective study. Pediatr Infect Dis J. 1997;16:354-8.
273.Oermann, CM, Starke, JR, Seilheimer, DK. Pulmonary disease caused by Mycobacterium kansasii in a patient with cystic fibrosis. Pediatr Infect Dis J. 1997;16:257-9.
274.Oliver, A, Maiz, L, Canton, R, Escobar, H, Baquero, F, Gomez-Mampaso, E. Nontuberculous mycobacteria in patients with cystic fibrosis. Clin Infect Dis. 2001;32:1298-303.
275.Tomashefski, JF Jr, Stern, RC, Demko, CA, Doershuk, CF. Nontuberculous mycobacteria in cystic fibrosis. An autopsy study. Am J Respir Crit Care Med. 1996;154:523-8.
276.Cullen, AR, Cannon, CL, Mark, EJ, Colin, AA. Mycobacterium abscessus infection in cystic fibrosis. Colonization or infection? Am J Respir Crit Care Med. 2000;161:641-5.
277.Olivier, KN, Weber, DJ, Wallace, RJ Jr, et al. Nontuberculous mycobacteria, I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med. 2003;167:828-34.
278.Bange, FC, Brown, BA, Smaczny, C, Wallace, RJ Jr, Bottger, EC. Lack of transmission of Mycobacterium abscessus among patients with cystic fibrosis attending a single clinic. Clin Infect Dis. 2001;32:1648-50.
279.Brown, K, Rosenthal, M, Bush, A. Fatal invasive aspergillosis in an adolescent with cystic fibrosis. Pediatr Pulmonol. 1999;27:130-3.
280.Maguire, CP, Hayes, JP, Hayes, M, Masterson, J, FitzGerald, MX. Three cases of pulmonary aspergilloma in adult patients with cystic fibrosis. Thorax. 1995;50:805-6.
281.Burns, JL, Van Dalfsen, JM, Shawar, RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis. 1999;179:1190-96.
282.Bargon, J, Dauletbaev, N, Kohler, B, Wolf, M, Posselt, HG, Wagner, TO. Prophylactic antibiotic therapy is associated with an increased prevalence of Aspergillus colonization in adult cystic fibrosis patients. Respir Med. 1999;93:835-8.
283.Cimon, B, Carrere, J, Vinatier, JF, Chazalette, JP, Chabasse, D, Bouchara, JP. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 2000;19:53-6.
284.Geller, DE, Kaplowitz, H, Light, MJ, Colin, AA. Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Chest. 1999;116:639-46.
285.Mastella, G, Rainisio, M, Harms, HK, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis. Eur Respir J. 2000;16:464-71.
286.Bartley, J. Construction. In: Olmstead, RN, ed. Association for Professionals in Infection Control (APIC), Infection Control and Applied Epidemiology: Principles and Practice. St. Louis, MO: Mosby Year Book Publications; 1996:104:16.
287.Pegues, DA, Lasker, BA, McNeil, MM, Hamm, PM, Lundal, JI, Kubak, BM. Cluster of cases of invasive aspergillosis in a transplant intensive care unit: Evidence of person-to-person transmission. Clin Infect Dis. 2002;34:412-16.
288.Ramsey, BW, Gore, EJ, Smith, AL, Cooney, MK, Redding, GJ, Foy, H. The effect of respiratory viral infections on patients with cystic fibrosis. Am J Dis Child. 1989;143:662-8.
289.Hiatt, PW, Grace, SC, Kozinetz, CAet al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatr. 1999;103:619-26.
290.Pribble, CG, Black, PG, Bosso, JA, Turner, RB. Clinical manifestations of exacerbations of cystic fibrosis associated with nonbacterial infections. J Pediatr. 1990;117:200-4.
291.Wang, EE, Prober, CG, Manson, B, Corey, M, Levison, H. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med. 1984;311:1653-8.
292.Smyth, AR, Smyth, RL, Tong, CY, Hart, CA, Heaf, DR. Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis. Arch Dis Child. 1995;73:117-20.
293.Armstrong, D, Grimwood, K, Carlin, JB, et al. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol. 1998;26:371-9.
294.Hall, CB. Respiratory syncytial virus: a continuing culprit and conundrum. J Pediatr. 1999;135:27.
295.Hall, CB, Powell, KR, MacDonald, NE, et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med. 1986;315:7781.
296.From the Centers for Disease Control and Prevention. Update: respiratory syncytial virus activity—United States, 1997-98 season. JAMA. 1998;279:264-5.
297.Abman, SH, Ogle, JW, Butler-Simon, N. Rumack, CM, Accurso, FJ. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr. 1988;113:826-30.
298.Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics. 1998;102:1211-6.
299.Arnold, SR, Wang, EE, Law, BJ, et al. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J. 1999;18:866-9.
300.Piedra, PA, Grace, S, Jewell, A, et al. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J. 1996;15:2331.
301.Bridges, CB, Fukuda, K, Uyeki, TM, Cox, NJ, Singleton, JA. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices AC1P). MMWR Recomm Rep. 2002;51(RR-3):131.
302.Ferson, MJ, Morton, JR, Robertson, PW. Impact of influenza on morbidity in children with cystic fibrosis. J Paediatr Child Health. 1991;27:308-11.
303.Conway, SP, Simmonds, EJ, Littlewood, JM. Acute severe deterioration in cystic fibrosis associated with influenza A virus infection. Thorax. 1992;47:112-4.
304.Gruber, WC, Campbell, PW, Thompson, JM, Reed, GW, Roberts, B, Wright, PE. Comparison of live attenuated and inactivated influenza vaccines in cystic fibrosis patients and their families: results of a 3-year study. J Infect Dis. 1994;169:241-7.
305.Gross, PA, Denning, CR, Gaerlan, PF, et al. Annual influenza vaccination: immune response in patients over 10 years. Vaccine. 1996;14:1280-4.
306.Gern, JE, Busse, WW. Association of rhinovirus infections with asthma. Clin Microbiol Rev. 1999;12:9-18.
307.Yankaskas, JR, Mallory, GB Jr. Lung transplantation in cystic fibrosis: consensus conference statement. Chest. 1998;113:217-26.
308.Aris, RM, Gilligan, PH, Neuringer, IP, Gott, KK, Rea, J, Yankaskas, JR. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med. 1997;155:1699-704.
309.LiPuma, JJ. Burkholderia cepacia: a contraindication to lung transplantation in CF? Transpl Infect Dis. 2001;3:150-62.
310.Snell, GI, de Hoyos, A, Krajden, M, Winton, T, Maurer, JR. Pseudomonas cepacia in lung transplant recipients with cystic fibrosis. Chest. 1993;103:466-71.
311.Steinbach, S, Sun, L, Jiang, RZ, et al. Transmissibility of Pseudomonas cepacia infection in clinic patients and lung-transplant recipients with cystic fibrosis. N Engl J Med. 1994;331:981-7.
312.Chaparro, C, Maurer, J, Gutierrez, C, et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med. 2001;163:43-8.
313.Walter, S, Gudowius, P, Bosshammer, J, et al. Epidemiology of chronic Pseudomonas aeruginosa infections in the airways of lung transplant recipients with cystic fibrosis. Thorax. 1997;52:318-21.
314.Kanj, SS, Tapson, V, Davis, RD, Madden, J, Browning, I. Infections in patients with cystic fibrosis following lung transplantation. Chest. 1997;112:924-30.
315.Nunley, DR, Grgurich, W, Iacono, AT, et al. Allograft colonization and infections with Pseudomonas in cystic fibrosis lung transplant recipients. Chest. 1998;113:1235-43.
316.Nunley, DR, Ohori, P, Grgurich, WF, et al. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest. 1998;114:1321-9.
317.Paradowski, LJ. Saprophytic fungal infections and lung transplantation—revisited. J Heart Lung Transplant. 1997;16:524-31.
318.Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR Morb Mortal Wkly Rep. 2000;49(RR-10):1125.
319.Walters, S, Smith, EG. Pseudomonas cepacia in cystic fibrosis: transmissibility and its implications. Lancet. 1993;342:34.
320.Bennett, SM. ‘Patient perspective’ - psychological effects of barrier nursing isolation. Australian Nurses J. 1983;12:36-7, 44.
321.Gammon, J. Analysis of the stressful effects of hospitalization and source isolation on coping and psychological constructs. Nursing Pract. 1998;4:8496.
322.Gammon, J. The psychological consequences of source isolation: a review of the literature. J Clin Nursing. 1999;8:1321.
323.Kennedy, P, Hamilton, LR. Psychological impact of the management of methicillin-resistant Staphylococcus aureus (MRSA) in patients with spinal cord injury. Spinal Cord. 1997;35:617-9.
324.Knowles, HE. The experience of infectious patients in isolation. Nursing Times. 1993;89:53-6.
325.Oldman, T. Isolated cases. Nursing Times. 1998;94:6770.
326.Wilkins, EG, Ellis, ME, Dunbar, EM, Gibbs, A. Does isolation of patients with infections induce mental illness? J Infect. 1988;17:43-7.
327.Powazek, M, Goff, JR, Schyving, J, Paulson, MA. Emotional reactions of children to isolation in a cancer hospital. J Pediatr. 1978;92:834-7.
328.Casey, V. The child in isolation: treatment or abuse? Nursing Praxis in N Zeal. 1989;5:1922.
329.Ward, D. Infection control: reducing the psychological effects of isolation. British J Nursing. 2000;9:162-70.
330.Campbell, T. Feelings of oncology patients about being nursed in protective isolation as a consequence of cancer chemotherapy treatment. J Adv Nurs. 1999;30:439-47.
331.Walter, S. Association of Cystic Fibrosis Adults Survey 1994. London: Cystic Fibrosis Trust; 1995.
332.Smith, DL, Gumery, LB, Smith, EG, Stableforth, DE, Kaufmann, ME, Pitt, TL. Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit evidence of person-to-person transmission. J Clin Microbiol. 1993;31:3017-22.
333.Patterson, JE, Vecchio, J, Pantelick, EL, et al. Association of contaminated gloves with transmission of Acinetobacter calcoaceticus var. anitratus in an intensive care unit. Am J Med. 1991;91:479-83.
334.Doebbeling, BN, Pfaller, MA, Houston, AK, Wenzel, RP. Removal of nosocomial pathogens from the contaminated glove. Implications for glove reuse and hand washing. Ann Intern Med. 1988;109:394-8.
335.Occupational exposure to bloodborne pathogens—OSHA Final rule. Federal Register. 1991;56:64004-182.
336.Rutala, WA. Disinfection and sterilization of patient-care items. Infect Control Hosp Epidemiol. 1996;17:377-84.
337.Chan-Myers, H, McAlister, D, Antonoplos, p. Natural bioburden levels detected on rigid lumened medical devices before and after cleaning. Am J Infect Control. 1997;25:471-6.
338.Jacobs, FT, Wang, J-H, Gorham, RA, Roberts, CG. Cleaning: principles, methods and benefits. In: Rutala, WA ed. Disinfection, Sterilization and Antisepsis in Health Care. Washington, DC: Association for Professionals in Infection Control and Epidemiology Inc; 1998.
339.Rutala, WA, Gergen, MF, Jones, JF, Weber, DJ. Levels of microbial contamination on surgical instruments. Am J Infect Control. 1998;26:143-5.
340.Alfa, MJ, DeGagne, P, Olson, N, Puchalski, T. Comparison of ion plasma, vaporized hydrogen peroxide, and 100% ethylene oxide sterilizers to the 12/88 ethylene oxide gas sterilizer. Infect Control Hosp Epidemiol. 1996;17:92100.
341.Bryce, EA, Chia, E, Logelin, G, Smith, JA. An evaluation of the AbTox Plazlyte Sterilization System. Infect Control Hosp Epidemiol. 1997;18:646-53.
342.Levy, RV. Sterile filtration of liquids and gases. In: Block, SS, ed. Disinfection, Sterilization and Preservation. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:795822.
343.Singh, J, Bhatia, R, Gandhi, JC, et al. Outbreak of viral hepatitis B in a rural community in India linked to inadequately sterilized needles and syringes. Bull World Health Organ. 1998;76:93-8.
344.Agerton, T, Valway, S, Gore, B, et al. Transmission of a highly drug-resistant strain (strain Wl) of Mycobacterium tuberculosis. Community outbreak and nosocomial transmission via a contaminated bronchoscope. JAMA. 1997;278:1073-7.
345.Bronowicki, JP, Venard, V, Botte, C, et al. Patient-to-patient transmission of hepatitis C virus during colonoscopy. N Engl J Med. 1997;337:237-40.
346.Michele, TM, Cronin, WA, Graham, NM, et al. Transmission of Mycobacterium tuberculosis by a fiberoptic bronchoscope. Identification by DNA fingerprinting. JAMA. 1997;278:1093-5.
347.Sattar, SA, Lloyd-Evans, N, Springthorpe, VS, Nair, RC. Institutional outbreaks of rotavirus diarrhoea: potential role of fomites and environmental surfaces as vehicles for virus transmission. J Hyg (Land). 1986;96:277-89.
348.Ward, RL, Bernstein, DI, Knowlton, DR, et al. Prevention of surface-to-human transmission of rotaviruses by treatment with disinfectant spray. J Clin Microbiol. 1991;29:1991-6.
349.Sattar, SA, Jacobsen, H, Springthorpe, VS, Cusack, TM, Rubino, JR. Chemical disinfection to interrupt transfer of rhinovirus type 14 from environmental surfaces to hands. Appl Environ Microbiol. 1993;59:1579-85.
350.Gwaltney, JM Jr, Hendley, JO. Transmission of experimental rhinovirus infection by contaminated surfaces. Am J Epidemiol. 1982;116:828-33.
351.Seto, WH, Ching, TY, Yuen, KY, Lam, WK. Evaluating the sterility of disposable wall oxygen humidifiers, during and between use on patients. Infect Control Hosp Epidemiol. 1990;11:604-5.
352.Golar, SD, Sutherland, LL, Ford, GT. Multipatient use of prefilled disposable oxygen humidifiers for up to 30 days: patient safety and cost analysis. Respir Care. 1993;38:343-7.
353.Henderson, E, Ledgerwood, D, Hope, KM, et al. Prolonged and multipatient use of prefilled disposable oxygen humidifier bottles: safety and cost. Infect Control Hosp Epidemiol. 1993;14:463-8.
354.Food and Drug Administration. Enforcement Priorities for Single-Use Devices Reprocessed by Third Parties and Hospitals. Rockville, MD: Food and Drug Administration; 2000.
355.Rosenfeld, M, Emerson, J, Astley, S, et al. Home nebulizer use among patients with cystic fibrosis. J Pediatr. 1998;132:125-31.
356.Vassal, S, Taamma, R, Marty, N, et al. Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis. Am J Infect Control. 2000;28:347-51.
357.Arnow, PM, Chou, T, Weil, D, Shapiro, EN, Kretzschmar, C. Nosocomial Legionnaires' disease caused by aerosolized tap water from respiratory devices. J Infect Dis. 1982;146:460-7.
358.Sheth, NK, Post, GT, Wisniewski, TR, Uttech, BV. Multidose vials versus single-dose vials: a study in sterility and cost-effectiveness. J Clin Microbiol. 1983;17:377-9.
359.Harbarth, S, Sudre, P, Dharan, S, Cadenas, M, Pittet, D. Outbreak of Enterobacter cloacae related to understating, overcrowding, and poor hygiene practices. Infect Control Hosp Epidemiol. 1999;20:598603.
360.Cunha, BA, Klimek, JJ, Gracewski, J, McLaughlin, JC, Quintiliani, R. A common source outbreak of Acinetobacter pulmonary infections traced to Wright respirometers. Postgrad Med J. 1980;56:169-72.
361.Irwin, RS, Demers, RR, Pratter, MR, et al. An outbreak of Acinetobacter infection associated with the use of a ventilator spirometer. Respir Care. 1980;25:232-7.
362.Rutala, DR, Rutala, WA, Weber, DJ, Thomann, CA. Infection risks associated with spirometry. Infect Control Hosp Epidemiol. 1991;12:8992.
363.Rutala, WA, Weber, DJ. Surface disinfection: should we do it? J Hosp Infect. 2001;48:S64-68.
364.Roberts, FJ, Cockcroft, WH, Johnson, HE. A hot water disinfection method for inhalation therapy equipment. Can Med Assoc J. 1969;101:30-2.
365.Ayliffe, GA, Collins, BJ, Lowbury, EJ, Babb, JR, Lilly, HA. Ward floors and other surfaces as reservoirs of hospital infection. J Hyg (Lond). 1967;65:515-36.
366.Russell, AD, McDonnell, G. Concentration: a major factor in studying bio-cidal action. J Hosp Infect. 2000;44:13.
367.Rutala, WA, Cole, EC. Antiseptics and disinfectants—safe and effective? Infect Control. 1984;5:215-8.
368.Weber, DJ, Rutala, WA. Occupational risks associated with the use of selected disinfectants and sterilants. In: Rutala, WA ed. Disinfection, Sterilization and Antisepsis in Health Care. Champlain, NY: Polyscience Publications; 1998:211226.
369.Regelmann, WE, Elliott, GR, Warwick, WJ, Clawson, CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis. 1990;141:914-21.
370.Campos, JM. Culture and isolation. In: Murray, PR, Baron, EJ, Pfaller, MA, Tenover, FC, Yolken, RH, eds. Manual of Clinical Microbiology. 7th ed. Washington, DC: ASM Press; 1999:604-13.
371.Ziegler, T, Cox, NJ. Influenza viruses. In: Murray, PR, Baron, EJ, Pfaller, MA, Tenover, FC, Yolken, RH, eds. Manual of Clinical Microbiology. 7 ed. Washington, DC: ASM Press; 1999:928-35.
372.Waner, JL. Parainfluenza viruses. In: Murray, PR, Baron, EJ, Pfaller, MA, Tenover, FC, Yolken, RH, eds. Manual of Clinical Microbiology. 7 ed. Washington, DC: ASM Press; 1999:936-41.
373.Tristram, DA, Welliver, RC. Respiratory syncytial virus. In: Murray, PR, Baron, EJ, Pfaller, MA, Tenover, FC, Yolken, RH, eds. Manual of Clinical Microbiology. 7th ed. Washington, DC: ASM Press; 1999:942-50.
374.Wadell, G, Allard, A, Hierholzer, JC. Adenoviruses. In: Murray, PR, Baron, EJ, Pfaller, MA, Tenover, FC, Yolken, RH, eds. Manual of Clinical Microbiology. 7th ed. Washington, DC: ASM Press; 1999:970-81.
375.Kiska, DL, Kerr, A, Jones, MC, et al. Accuracy of four commercial systems for identification of Burkholderia cepacia and other gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis. J Clin Microbiol. 1996;34:886-91.
376.van Pelt, C, Verduin, CM, Goessens, WH, et al. Identification of Burkholderia spp. in the clinical microbiology laboratory: comparison of conventional and molecular methods. J Clin Microbiol. 1999;37:2158-64.
377.Shelly, DB, Spilker, T, Gracely, EJ, Coenye, T, Vandamme, P, LiPuma, JJ. Utility of commercial systems for identification of Burkholderia cepacia complex from cystic fibrosis sputum culture. J Clin Microbiol. 2000;38:3112-5.
378.American Institutes of Architects. Guidelines for Design and Construction of Hospital and Health Care Facilities. Washington, DC: American Institute of Architects Press; 2001:15.
379.Guidelines for preventing the transmission of Mycobacteria tuberculosis in health-care facilities, 1994. MMWR Morb Mortal Wkly Rep. 1994;43:(RR-13):1132.
380.Centers for Disease Control and Prevention. Recommended childhood immunization schedule—United States, 2002. MMWR. 2002;51:3133.
381.Advisory Commiittee on Immunization Practice (ACIP). Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practice(ACIP). MMWR Morb Mortal Wkly Rep. 2000;49:135.
382.Rutala, WA, Weber, DJ, Gergen, MF, Gratta, AR. Efficacy of a washer-pasteurizer for disinfection of respiratory-care equipment. Infect Control Hosp Epidemiol. 2000;21:333-6.
383.Latimer, JM, Matsen, JM. Microwave oven irradiation as a method for bacterial decontamination in a clinical microbiology laboratory. J Clin Microbiol. 1977;6:340-2.
384.Robbins, J, Cromwell, P, Korones, DN. Swimming and central venous catheter-related infections in the child with cancer. J Pediatr Oncol Nurs. 1999;16:51-6.
385.Howell, PB, Walters, PE, Donowitz, GR, Farr, BM. Risk factors for infection of adult patients with cancer who have tunnelled central venous catheters. Cancer. 1995;75:1367-75.
386.O'Grady, NP, Alexander, M, Delinger, EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2002;51(RR-10):129.
387.Evans, CE, Haynes, RB. Patient compliance. In: Rakel, RE, ed. Textbook of Family Practice. 4th ed. Philadelphia, PA: WB Saunders Co; 1990:371379.
388.Vandamme, P, Holmes, B, Vancanneyt, M, et al. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int J Syst Bacterial. 1997;47:1188-200.
389.Vandamme, P, Mahenthiralingam, E, Holmes, B, et al. Identification and population structure of Burkholderia stabilis sp. nov. (formerly Burkholderia cepacia genomovar IV). J Clin Microbiol. 2000;38:1042-7.
390.Gillis, M, Van, TV, Bardin, R. Polyphasic taxonomy in the genus Burkholderia leading to an emended description of the genus and proposition of Burkholderia vietnamiensis sp. nov. for N2-fixing isolates from rice in Vietnam. Int J Syst Bacterial. 1995;45:274.
391.Coenye, T, LiPuma, JJ, Henry, D, et al. Burkholderia cepacia genomovar VI, a new member of the Burkholderia cepacia complex isolated from cystic fibrosis patients. Int J Syst Evol Microbiol. 2001;51:271-9.
392.Coenye, T, Mahenthiralingam, E, Henry, D, et al. Burkholderia ambifaria sp. nov., a novel member of the Burkholderia cepacia complex including biocontrol and cystic fibrosis-related isolates. Int J Syst Evol Microbiol. 2001;51:1481-90.
393.Vandamme, P, Henry, D, Coenye, T, et al. Burkholderia anthina sp. nov. and Burkholderia pyrrocinia, two additional Burkholderia cepacia complex bacteria, may confound results of new molecular diagnostic tools. FEMS Immunol Med Microbiol. 2002;33:143-9.
394.Stableforth, DE, Smith, DL. Pseudomonas cepacia in cystic fibrosis. Thorax. 1994;49:629-30.
395.Weber, DJ, Rutala, WA. Role of environmental contamination in the transmission of vancomycin-resistant enterococci. Infect Control Hosp Epidemiol. 1997;18:306-9.